ND Partners, LLC
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Taurolidine/heparin(Defencath / Neutrolin) | Approved | Antimicrobial/antithrombotic catheter lock solutionSmall molecule | Chronic Kidney Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
January 2028 (1)
Taurolidine/heparin · Defencath / NeutrolinPhase 3Central Line Associated Blood Stream Infections (CLABSI)
Est. primary completion 2028-01 · NCT06822426 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.